Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation

Search Page

Filters

My NCBI Filters

Text availability

Article attribute

Article type

Publication date

Search Results

372 results

Filters applied: . Clear all
Results are displayed in a computed author sort order. The Results By Year timeline is not available.
Page 1
Tissue engineering and regenerative medicine in musculoskeletal oncology.
Holzapfel BM, Wagner F, Martine LC, Reppenhagen S, Rudert M, Schuetz M, Denham J, Schantz JT, Hutmacher DW. Holzapfel BM, et al. Among authors: denham j. Cancer Metastasis Rev. 2016 Sep;35(3):475-87. doi: 10.1007/s10555-016-9635-z. Cancer Metastasis Rev. 2016. PMID: 27566370 Review.
A humanized orthotopic tumor microenvironment alters the bone metastatic tropism of prostate cancer cells.
McGovern JA, Bock N, Shafiee A, Martine LC, Wagner F, Baldwin JG, Landgraf M, Lahr CA, Meinert C, Williams ED, Pollock PM, Denham J, Russell PJ, Risbridger GP, Clements JA, Loessner D, Holzapfel BM, Hutmacher DW. McGovern JA, et al. Among authors: denham j. Commun Biol. 2021 Aug 30;4(1):1014. doi: 10.1038/s42003-021-02527-x. Commun Biol. 2021. PMID: 34462519 Free PMC article.
Tumour innervation and neurosignalling in prostate cancer.
March B, Faulkner S, Jobling P, Steigler A, Blatt A, Denham J, Hondermarck H. March B, et al. Among authors: denham j. Nat Rev Urol. 2020 Feb;17(2):119-130. doi: 10.1038/s41585-019-0274-3. Epub 2020 Jan 14. Nat Rev Urol. 2020. PMID: 31937919 Review.
Impact of androgen suppression and zoledronic acid on bone mineral density and fractures in the Trans-Tasman Radiation Oncology Group (TROG) 03.04 Randomised Androgen Deprivation and Radiotherapy (RADAR) randomized controlled trial for locally advanced prostate cancer.
Denham JW, Nowitz M, Joseph D, Duchesne G, Spry NA, Lamb DS, Matthews J, Turner S, Atkinson C, Tai KH, Gogna NK, Kenny L, Diamond T, Smart R, Rowan D, Moscato P, Vimieiro R, Woodfield R, Lynch K, Delahunt B, Murray J, D'Este C, McElduff P, Steigler A, Kautto A, Ball J. Denham JW, et al. BJU Int. 2014 Sep;114(3):344-53. doi: 10.1111/bju.12497. Epub 2014 Feb 11. BJU Int. 2014. PMID: 24512527 Clinical Trial.
Time to biochemical failure and prostate-specific antigen doubling time as surrogates for prostate cancer-specific mortality: evidence from the TROG 96.01 randomised controlled trial.
Denham JW, Steigler A, Wilcox C, Lamb DS, Joseph D, Atkinson C, Matthews J, Tai KH, Spry NA, Christie D, Gleeson PS, Greer PB, D'Este C; Trans-Tasman Radiation Oncology Group 96.01 Trialists. Denham JW, et al. Lancet Oncol. 2008 Nov;9(11):1058-68. doi: 10.1016/S1470-2045(08)70236-5. Epub 2008 Oct 15. Lancet Oncol. 2008. PMID: 18929505
Quality of life in men with locally advanced prostate cancer treated with leuprorelin and radiotherapy with or without zoledronic acid (TROG 03.04 RADAR): secondary endpoints from a randomised phase 3 factorial trial.
Denham JW, Wilcox C, Joseph D, Spry NA, Lamb DS, Tai KH, Matthews J, Atkinson C, Turner S, Christie D, Gogna NK, Kenny L, Duchesne G, Delahunt B, McElduff P. Denham JW, et al. Lancet Oncol. 2012 Dec;13(12):1260-70. doi: 10.1016/S1470-2045(12)70423-0. Epub 2012 Nov 12. Lancet Oncol. 2012. PMID: 23151431 Clinical Trial.
372 results